15Jul 2023
First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis

First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis

Toripalimab, camrelizumab, and tislelizumab combined with chemotherapy have shown promising results in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). The results indicated that the immunotherapy combinations significantly improved overall and progression-free survival. However, the additional costs associated with these treatments were substantial. Among the three combinations, toripalimab plus chemotherapy was identified as the most cost-effective option.

  • #ent

Like

Save

Share